NeuroPace rises on NIH grant to test device in childhood-onset epilepsy

NeuroPace

30/06/2021 16:09

** Shares of medical device maker NeuroPace Inc  NPCE.O 
rise 2.6% to $24.08
    ** Co receives National Institutes of Health grant, which
will provide up to $9.3 mln over five years to test NPCE's
neuromodulation device, RNS System, in treating seizures
associated with Lennox-Gastaut Syndrome  urn:newsml:reuters.com:*:nGNXb0QJdf
    ** LGS is a form of childhood-onset epilepsy that causes
cognitive dysfunction and frequent seizures that often lead to
injury
    ** A NIH-funded study is expected to start enrolling
patients in H2 of 2022 - NPCE
    ** RNS system is currently approved in U.S. for patients 18
years of age and older with drug-resistant focal epilepsy
    ** Stock down 3.5% since April 22 IPO

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com))